The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, today released the agenda for its upcoming three-day Cell & Gene Meeting on the Mesa annual conference, October 4-6, 2017.
Organized by ARM and the UC San Diego Sanford Stem Cell Clinical Center, the Cell & Gene Meeting on the Mesa is three-day conference featuring three distinct parts: the program’s two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium.
The event’s Partnering Forum, held this year on October 4-5, features more than 90 speakers, presenting on the most pressing sector issues and focus areas in a variety of expert-led plenary sessions, featured talks, panels and workshops, including:
Plenary Session:
– Implications of CAR-T Commercialization: What Does Approval Mean?
Featured Talk:
– FDA CBER Director Wilson Bryan, M.D.: Regenerative Medicine Advanced Therapy (RMAT) Designation
Panels:
– Spotlight: Tissue Engineering
– Navigating Regenerative Medicine Technology Assessment and Reimbursement in North America and Europe
– Gene Therapy: Building the Gene Medicine Pipeline Through Next-Generation Technologies
– The Gene Editing Challenge: Validating Platform Technologies
– Accelerating Regulatory Development of Advanced Therapy Medicine Products for Patients in Need
– Spotlight: Financing the Cell and Gene Therapy Sector
– iPSCs for Therapeutic Applications
Workshops:
– Doing Business in Japan: Beyond Japan’s Regulatory Renovation
– Manufacturing Gene Medicines
– Development of Cellular Therapies
– Health Technology Assessment
– Helping Your Cell Therapy Go Global
– Logistics, Automation and Standards
Throughout the two-day Partnering Forum, event participants can also attend presentations by more than 65 prominent publicly traded and emerging private companies, highlighting clinical and commercial progress in cell therapy, gene and gene-modified cell therapy, tissue engineering, biomaterials and more. In addition to their presentations, representatives from these organizations will also be available for one-on-one partnering opportunities throughout the conference.
Slate of presenting companies:
4D Molecular Therapeutics; Abeona Therapeutics; Acucela; Adaptimmune; AGTC; American Gene Technologies; Asterias Biotherapeutics; Athersys; Audentes Therapeutics; AVROBIO; Bellicum Pharmaceuticals; Benitec Biopharma; Biostage; BioTime; bluebird bio; BlueRock Therapeutics; B-MoGen Biotechnologies; Bone Therapeutics; Caladrius Biosciences; Capricor Therapeutics; Cell Medica; CellSeed; Cellular Dynamics International; Cesca Therapeutics; CRISPR Therapeutics; Cynata Therapeutics; DiscGenics; Fate Therapeutics; Fibrocell; GammaDelta Therapeutics; Healios; Histogenics; Homology Medicines; Intellia Therapeutics; jCyte; Juventas Therapeutics; Lysogene; MaxCyte; Medeor Therapeutics; MEDIPOST America; Mesoblast; MiMedx; MolMed; Orbsen Therapeutics; Orchard Therapeutics; Oxford BioMedica; PDC*line; Precision Biosciences; Promethera Biosciences; REGENXBIO; ReNeuron; Renova Therapeutics; RoosterBio; Sangamo Therapeutics; SCM Lifescience; Semma Therapeutics; Sentien Biotechnologies; Sigilon Therapeutics; StemBioSys; Synpromics; Terumo BCT; TiGenix; TxCell; Universal Cells; Vericel; ViaCyte; Vivet Therapeutics; WindMIL Therapeutics.
Following the close of the Partnering Forum on October 5, there will be a Public Forum presentation and reception held at the Sanford Consortium for Regenerative Medicine. Donna Skerrett, M.D., chief medical officer of Mesoblast, will introduce keynote speaker and Nobel Laureate Thomas Südhof, M.D., Professor of Molecular and Cellular Physiology; Neurology and Neurological Sciences; and Psychiatry and Behavioral Science at Stanford University; and Investigator at the Howard Hughes Medical Institute. Dr. Südhof’s presentation is titled, “Towards a Better Understanding of Neuropsychiatric Disorders: The Role of Synapses.”
The Scientific Symposium, held October 6 at the Salk Institute for Biological Studies, will feature numerous talks, panels and discussions led by prominent international scientists and more than 35 posters featuring the latest scientific discoveries in the world of regenerative medicine and advanced therapies. The discussions will cover scientific advances related to immuno-oncology; progenitors and stem cells; the use of tissue organoids in several biological applications; stem cells and cancer and more.
For full details on the agenda and further information about the event, please visit www.meetingonthemesa.com.
Registration is complimentary for investors and credentialed members of the media. For members of the media interested in attending, please contact Lyndsey Scull at lscull@alliancerm.org.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 270 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
